Simultaneous binding of FcγRI/CD64 and FcγRIIa/CD32a results in a fivefold increase in ADCC and ADCP activities against CD20+ tumour B cells in mice in vivo (122, 123). The gene discussed is FCGR1A; the disease is neoplasm.